Evidence map›Paper›PMID 30081846›Full record

ArticleBMC cancer2018

The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD.

Joel E Pacyna, Simon Kim, Kathleen Yost, Hillary Sedlacek, Daniel Petereit, Judith Kaur, Bruce Rapkin, Robert Grubb, Electra Paskett, George J Chang and 9 more

Registry-linked trialAbstract readClinical Trial ProtocolComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03103321 (Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03103321 phase3completednot on this map

Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men

TypeinterventionalSponsorAlliance for Clinical Trials in OncologyRan2017 to 2020Enrolled158ConditionsStage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate CancerArmsInternet-Based Intervention, Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Joel E PacynaMayo Clinic, Rochester, MN, USA.
Simon KimUniversity Hospitals, Case Western Reserve University, Cleveland, OH, USA.
Kathleen YostMayo Clinic, Rochester, MN, USA.
Hillary SedlacekUniversity Hospitals, Case Western Reserve University, Cleveland, OH, USA.
Daniel PetereitRegional Health, Rapid City, SD, USA.
Judith KaurMayo Clinic, Jacksonville, FL, USA.
Bruce RapkinAlbert Einstein Cancer Center, Bronx, NY, USA.
Robert GrubbMedical University of South Carolina, Charleston, SC, USA.
Electra PaskettOhio State University, Columbus, OH, USA.
George J ChangMD Anderson Cancer Center, Houston, TX, USA.
Jeff SloanAlliance Statistics And Data Center, Mayo Clinic, Rochester, MN, USA.
Ethan BaschUniversity of North Carolina, Chapel Hill, North Carolina, USA.
Brittny MajorAlliance Statistics And Data Center, Mayo Clinic, Rochester, MN, USA.
Paul NovotnyMayo Clinic, Rochester, MN, USA.
John TaylorUniversity of Chicago, Chicago, IL, USA.
Jan BucknerMayo Clinic, Rochester, MN, USA.
J Kellogg ParsonsMoores UC San Diego Comprehensive Cancer Center, San Diego, CA, USA.
Michael MorrisMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Jon C TilburtMayo Clinic, Rochester, MN, USA. tilburt.jon@mayo.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Collaborations and NCORP Collective ManagementUG1CA189823 · NCI · MAYO CLINIC ROCHESTER · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$120.6M
Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer CenterU10CA180791 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AGHAJANIAN, CAROL, MORRIS, MICHAEL J · 2014 to 2018
$4.6M
Decision Aids to Address Prostate Cancer Disparities in Minority MenR01MD008934 · NIMHD · MAYO CLINIC ROCHESTER · PI KIM, SIMON P, TILBURT, JON C · 2014 to 2018
$1.9M
NCATS NIH HHS UL1 TR002377NCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180791NCI NIH HHS UG1 CA189823NCI NIH HHS UG1CA189823NIMHD NIH HHS R01 MD008934NIMHD NIH HHS R01MD008934
6 · The paper itself

Abstract

backgroundTreatments for localized prostate cancer present challenging tradeoffs in the face of uncertain treatment benefits. These options are best weighed in a process of shared decision-making with the patient's healthcare team. Minority men experience disparities in prostate cancer outcomes, possibly due in part to a lack of optimal communication during treatment selection. Decision aids facilitate shared decision-making, improve knowledge of treatment options, may increase satisfaction with treatment choice, and likely facilitate long-term quality of life. METHODS/

designThis study will compare the effect of two evidence-based decision aids on patient knowledge and on quality of life measured one year after treatment, oversampling minority men. One decision aid will be administered prior to specialist consultation, preparing patients for a treatment discussion. The other decision aid will be administered within the consultation to facilitate transparent, preference-sensitive, and evidence-informed deliberations. The study will utilize a four-arm, block-randomized design to test whether each decision aid alone (Arms 1 and 2) or in combination (Arm 3) can improve patient knowledge and quality of life compared to usual care (Arm 4). The study, funded by the National Cancer Institute's Community Oncology Research Program (NCORP), will be deployed within select institutions that have demonstrated capacity to recruit minority populations into urologic oncology trials. DISCUSSION: Upon completion of the trial, we will have 1) tested the effectiveness of two evidence-based decision aids in enhancing patients' knowledge of options for prostate cancer therapy and 2) estimated whether decision aids may improve patient quality of life one year after initial treatment choice.

trial registrationClinicaltrials.gov: NCT03103321 . The trial registration date (on ClinicalTrials.gov) was April 6, 2017.

Indexed as

Clinical Decision-MakingDecision Support TechniquesPatient ParticipationChoice BehaviorComparative Effectiveness ResearchHealth Knowledge, Attitudes, PracticeHumansMaleMulticenter Studies as TopicNeoplasm GradingNeoplasm StagingPatient Education as TopicPredictive Value of TestsProstatic NeoplasmsQuality of LifeRandomized Controlled Trials as TopicClinical trialDecision aidProstate cancerShared decision-making

Identifiers

PMID30081846
PMCPMC6080528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.